Skip to content
Pharmacology & Mechanisms

GLP-1

Glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The therapeutic target of blockbuster drugs semaglutide, tirzepatide, and liraglutide.

Frequently Asked Questions

What is GLP-1?
Glucagon-like peptide-1, an incretin hormone that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. The therapeutic target of blockbuster drugs semaglutide, tirzepatide, and liraglutide.
Why is GLP-1 important in peptide research?
GLP-1 is a key pharmacological concept that determines how peptides interact with the body. Understanding this term helps practitioners optimize dosing protocols, predict therapeutic outcomes, and minimize side effects.

Related Terms

GIP

Glucose-dependent insulinotropic polypeptide, an incretin hormone that enhances insulin secretion and may regulate fat metabolism. Co-targeted alongside GLP-1 by tirzepatide and retatrutide for enhanced weight loss.

Receptor agonist

A molecule that binds to and activates a receptor, triggering a biological response. Semaglutide is a GLP-1 receptor agonist; ipamorelin is a ghrelin receptor agonist.

First-pass metabolism

The metabolism of an orally administered peptide by the gut wall and liver before it reaches systemic circulation. First-pass effect dramatically reduces oral bioavailability for most peptides.

Related Peptide Profiles

Semaglutide

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Ozempic) and weight management (Wegovy). Reduces appetite and slows gastric emptying.

Tirzepatide

A dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes (Mounjaro) and weight loss (Zepbound). Achieves 20–25% body weight reduction in clinical trials.

Liraglutide

A GLP-1 receptor agonist FDA-approved for type 2 diabetes (Victoza) and weight management (Saxenda). Administered as a daily injection.

← Back to full glossary